Jian Liang Lin

7411719, Aug 12, 2008

Jun 21, 2005

11/160364

David Miller - Wakefield MA, US
Barrett Comiskey - Shanghai, CN
Joseph M. Jacobson - Newton Centre MA, US
Bin Wu - Sharon MA, US
Charles Howie Honeyman - Roslindale MA, US
Jian Lin - Acton MA, US

E Ink Corporation - Cambridge MA

G02B 26/00
G09G 3/34
G03G 13/04

359296, 345107, 430 32

A two-phase electrophoretic medium comprises a continuous phase and a discontinuous phase. The discontinuous phase comprises a plurality of droplets, each of which comprises a suspending fluid and at least one particle disposed within the suspending fluid and capable of moving through the fluid upon application of an electric field to the electrophoretic medium. The continuous phase surrounds and encapsulates the discontinuous phase. To reduce the humidity sensitivity of the medium, a non-ionizable or crystalline polymer may be used as the continuous phase.

7790707, Sep 7, 2010

Mar 21, 2007

11/726356

Ashis Saha - Stow MA, US
Xiang Yu - Acton MA, US
Mercedes Lobera - Bolton MA, US
Jian Lin - Walpole MA, US
Srinivasa R. Cheruku - Lexington MA, US
Oren Becker - Mevaseret Zion, IL
Yael Marantz - Kadima, IL
Nili Schutz - Tel-Aviv, IL

EPIX Pharmaceuticals Inc. - Lexington MA

A61K 31/397
A61K 31/4166
C07D 205/04
C07D 403/02
C07D 403/06

51421001, 51421017, 51421018, 5142102, 514392, 5483147, 5483164, 5483255, 548950, 548953

The present invention relates to compounds that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. In certain embodiments, the compounds of the invention relate to aryl oxoimidazolidinyls.

7848007, Dec 7, 2010

Jul 3, 2008

12/167290

David D. Miller - Wakefield MA, US
Barrett Comiskey - Shanghai, CN
Joseph M. Jacobson - Newton Centre MA, US
Bin Wu - Sharon MA, US
Charles Howie Honeyman - Roslindale MA, US
Jian Lin - Acton MA, US

E Ink Corporation - Cambridge MA

G02B 26/00
G03G 17/04

359296, 430 32

A two-phase electrophoretic medium comprises a continuous phase and a discontinuous phase. The discontinuous phase comprises a plurality of droplets, each of which comprises a suspending fluid and at least one particle disposed within the suspending fluid and capable of moving through the fluid upon application of an electric field to the electrophoretic medium. The continuous phase surrounds and encapsulates the discontinuous phase. To reduce the humidity sensitivity of the medium, a non-ionizable or crystalline polymer may be used as the continuous phase.

7855193, Dec 21, 2010

Jul 24, 2006

11/491766

Ashis K. Saha - Stow MA, US
Nili Schutz - Tel-Aviv, IL
Xiang Yu - Acton MA, US
Dilara McCauley - Cambridge MA, US
Mercedes Lobera - Concord MA, US
Yael Marantz - Kadima, IL
Jian Lin - Walpole MA, US
Srinivasa R. Cheruku - Lexington MA, US
Pini Orbach - Needham MA, US
Anurag Sharadendu - Bedford MA, US
Robert Christian Penland - Watertown MA, US
Kimberley Gannon - Watertown MA, US
Sharon Shacham - Newton MA, US
Silvia Noiman - Herzliyya, IL
Oren Becker - Mevaseret Zion, IL

EPIX Pharmaceuticals, Inc. - Lexington MA

A61K 31/397
A61K 31/5377
A61K 31/4525
A61K 31/4025
A61K 31/343
C07D 411/06
C07D 405/06
C07D 205/04
C07D 307/80

51421019, 5142335, 514320, 514422, 514469, 544153, 546196, 548517, 548953, 549467

The present invention relates to compounds of the general formula (I) that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds may be used as immunomodulators, e. g. , for treating or preventing diseases such as autoimmune and related immune disorders including systemic lupus erythematosus, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, type I diabetes, uveitis, psoriasis, myasthenia gravis, rheumatoid arthritis, non-glomerular nephrosis, hepatitis, Behçet's disease, glomerulonephritis, chronic thrombocytopenic purpura, hemolytic anemia, hepatitis and Wegner's granuloma; and for treating other conditions.

8569282, Oct 29, 2013

Dec 11, 2008

12/747109

Efrat Ben-Zeev - K. Motzkin, IL
Dongli Chen - Brighton MA, US
Merav Fichman - Modi'in, IL
Shomir Ghosh - Brookline MA, US
Steffi Koerner - Medford MA, US
Jian Lin - Acton MA, US
Yael Marantz - Kadima, IL
Rosa E. Melendez - Toronto, CA
Pradyumna Mohanty - Woburn MA, US
Sharon Shacham - Chestnut Hill MA, US
Zhaoda Zhang - Andover MA, US

CytoPathfinder, Inc. - Tokyo

C07D 471/04
A61K 31/4375

51421018, 514312, 514320, 5142305, 514309, 514403, 514375, 514321, 5142531, 544105, 544364, 546157, 546196, 546141, 5483625, 548221

Chemokine receptor antagonists, in particular, compounds of Formula (I-A) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.

20080146811, Jun 19, 2008

Jul 22, 2005

11/658121

Hongfeng Deng - Acton MA, US
Jian Lin - Walpole MA, US
Zihong Guo - Southbury CT, US
Harold V. Meyers - Weston MA, US
Sherin S. Abdel-Meguid - Exton PA, US
Robert E. Babine - Carlsbad CA, US

C07D 401/12
C07D 209/14

5462774, 548495

The invention provides compounds, pharmaceutical compositions, and methods for the treatment of thromboembolic disorders, such as, for example, arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, or thromboembolic disorders in the chambers of the heart.

20100184749, Jul 22, 2010

Oct 12, 2007

12/445149

Merav Fichman - Modi'in, IL
Rosa E. Melendez - Woburn MA, US
Pradyumna Mohanty - Woburn MA, US
Jian Lin - Walpole MA, US
Dilara McCauley - Cambridge MA, US
Boaz Inbal - Kfar Shmuel, IL
Mercedes Lobera - Bolton MA, US
Pini Orbach - Tel Mond, IL
Ori Kalid - Tel Aviv, IL
Dongli Chen - Brighton MA, US
Yael Marantz - Kadima, IL
Michael Xie - Natick MA, US
Sharon Shacham - Chestnut Hill MA, US
Oren Becker - Mevaseret Zion, IL

EPIX Delaware ,Inc. - Lexington MA

A61K 31/549
C07D 417/06
A61P 37/06
A61P 17/06
A61P 19/02
A61P 9/10
A61P 11/00
A61P 13/12
A61P 1/16
A61P 3/10

5142228, 544 11

Chemokine receptor antagonists, in particular, compounds of Formula (I) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.

20100210633, Aug 19, 2010

Oct 12, 2007

12/445134

Jian Lin - Acton MA, US
Dongli Chen - Brighton MA, US
Steffi Koerner - Medford MA, US
Rosa E. Melendez - Woburn MA, US
Efrat Ben-Zeev - K. Motzkin, IL
Merav Fichman - Modi'i, IL
Yael Marantz - Kadima, IL
Oren Becker - Mevaseret Zion, IL
Dilara McCauley - Cambridge MA, US
Pini Orbach - Tel Mond, IL
Ashis K. Saha - Stow MA, US
Sharon Shacham - Chestnut Hill MA, US
Michael Xie - Natick MA, US

EPIX Delaware, Inc. - Lexington MA

A61K 31/541
C07D 405/06
A61K 31/453
A61P 3/10
A61P 3/04
A61P 37/06
A61P 17/06
A61P 9/10
A61P 13/12
A61P 1/16
C07D 211/62
A61K 31/445
C07D 207/16
A61K 31/40
A61K 31/4525
C07D 413/10
A61K 31/454
C07D 405/14
A61K 31/496
C07D 401/06
A61K 31/4545
C07D 401/04
C07D 417/06
C07D 413/06
A61K 31/5377

5142278, 546207, 514326, 546225, 514330, 548537, 514423, 546197, 514321, 546199, 514322, 544364, 51425311, 546189, 514316, 546194, 514318, 544 582, 544130, 5142355, 5142368

Chemokine receptor antagonists, in particular, compounds of Formula (I) that act as antagonists of the chemokine CCR2 receptor, including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leukocyte accumulation are described herein.